|Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
VALOR is Sunesis. Phase 3, randomized, double-blind, placebo-controlled, pivotal trial in patients with first relapsed ... More >>
|Date||Title|| || |
|12/10/13||Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS|
|Cardiff University-Sponsored LI-1 Trial Combination Arm Evaluated by DMEC
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of an investigator-sponsored trial of vosaroxin in combination with azacitidine in patients with myelodysplastic syndrome (MDS). The trial is being conducted at the Washington University School of Medicine under the direction of Meagan A. Jacoby, M.D., Ph.D., Instructor of Medicine, Div... |
|11/27/13||Sunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Nov. 27, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will be presenting at the Piper Jaffray 25th Annual Healthcare Conference on Tuesday, December 3rd at 2:00 PM Eastern Standard Time at The New York Palace in New York City.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast wil... |
|11/12/13||Sunesis Pharmaceuticals Reports Third Quarter Financial Results and Recent Highlights|
|Sunesis to Host Conference Call Today at 11AM Eastern Time
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended September 30, 2013. Loss from operations for the three and nine months ended September 30, 2013 was $7.8 million and $24.2 million, respectively. As of September 30, 2013, cash, cash equivalents and marketable securities totaled $45.5 million.
"The VALOR trial, which comple... |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Sunesis Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Sunesis is a biopharmaceutical company focused on new oncology therapeutics for the treatment of solid and hematologic cancers.
Listen to recent webcasts of presentation conference calls, earnings calls, and more.
Copyright © Sunesis Pharmaceuticals, Inc. 2010. All Rights Reserved.